Genmab (GMAB) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab A/S, a Danish biotechnology firm, has announced a capital increase through the issuance of 28,193 new shares following the exercise of employee warrants, which will result in approximately DKK 29.3 million in proceeds for the company. This capital increase represents a minor 0.04% expansion of Genmab’s share capital, with President and CEO Jan van de Winkel notably increasing his personal shareholding. The new ordinary shares, which are now fully negotiable and come with dividend rights, will be listed on the Nasdaq Copenhagen.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.